A deal to acquire Alkermes spinout Mural Oncology is Xoma’s fourth since June and the latest evidence of interest in buying ...

Mural Oncology has agreed to be acquired by biotechnology royalty aggregator XOMA Royalty in a deal worth up to $38.8 million. Mural on Wednesday said XOMA will pay an initial $2.035 a share in cash, ...

Xoma Royalty is ravenous for biotechs, and the Bay Area licensing aggregator has found its next meal in Mural Oncology. | ...

The agreement values Mural Oncology at up to $36.2 million, with shareholders set to receive a base cash payment and ...

Turnstone Stockholders Received $0.34 Per Share in Cash Plus Contingent Value Right - EMERYVILLE, Calif., Aug. 11, 2025 ...

Mural Oncology PLC (MURA) and XOMA Royalty Corporation (XOMA) announced on Wednesday that they have entered into a definitive ...

Shares of XOMA Royalty (XOMA) have gained 22.2% over the past four weeks to close the last trading session at $31.37, but ...

EMERYVILLE, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA ...

Thereafter, XOMA fully retains the 15 percent royalty associated with DSUVIA® commercial sales, and the 75 percent royalties generated from DoD purchases will be shared equally between XOMA and ...

XOMA Royalty sold the remaining Kinnate pipeline assets for a total of up to $270 million in upfront and milestone payments, plus royalties on commercial sales at ra ...